

Special Issue

Nervous System Diseases: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editors

Nervous system diseases include debilitating conditions, such as neurodegenerative disorders (Alzheimer's and Parkinson's), neuroinflammatory diseases (multiple sclerosis), and neurodevelopmental disorders (autism and epilepsy). Despite decades of research, effective treatments remain elusive for many of these conditions due to the complexity and multifactorial nature of their pathophysiology.

Recent advances in molecular biology, omics technologies, neuroimaging, and computational modeling are shedding new light on the underlying mechanisms of these diseases and revealing promising therapeutic targets. Innovative interventions, including gene therapies, stem-cell-based treatments, neuromodulation techniques, and personalized medicine approaches, are beginning to transform the landscape of nervous system therapeutics.

This Special Issue is to foster interdisciplinary dialogue among neuroscientists, clinicians, and biomedical researchers to close the gap between bench and bedside. By uniting diverse perspectives, this Special Issue seeks to accelerate progress toward effective, personalized treatments.

Guest Editors

Dr. Natalia Rozas

1. Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston (UTHealth), 7500 Cambridge Street, Suite 5456, Houston, TX 77054, USA

2. Department of Biomedical Sciences, Kansas College of Osteopathic Medicine, 217 E. Douglas Ave, Room 437, Wichita, KS 67202, USA

Dr. Cameron Jeter

Department of Biomedical Sciences, Kansas College of Osteopathic Medicine, 217 E. Douglas Ave, Room 437, Wichita, KS 67202, USA

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/242211

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).